New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO ® Across All Studied Patient and Disease Characteristics in Cohort of R May 6, 2024 by True Academy Comments are off Posted in:Stock Market & Investment NewsTagged with:Buy Sell ShareFTSEKLCIMalaysiaPelaburanSahamShare Trading See more Prev:Teradata (TDC) Reports Earnings Tomorrow: What To Expect Back: All Posts Next:Earnings To Watch: Lincoln Educational (LINC) Reports Q1 Results Tomorrow